Loading organizations...
§ Public · Menlo Park, CA, USA
VYNE Therapeutics is a technology company.
VYNE Therapeutics develops proprietary and differentiated therapies for immuno-inflammatory conditions. The company leverages its InhiBET™ BET Inhibitor Platform to tackle complex therapeutic challenges, aiming to question traditional assumptions and discover novel solutions. Its innovative scientific approach emphasizes re-engineering methods to deliver new medicines.
The company originated from the March 2020 merger of Foamix Pharmaceuticals Ltd. and Menlo Therapeutics, uniting experienced pharmaceutical professionals. This group of independent thinkers sought to transcend conventional industry approaches. David Domzalski, formerly CEO of Foamix, became President and CEO, guiding the company toward developing unexpected solutions in patient care.
VYNE Therapeutics focuses on patients with immuno-inflammatory diseases, providing medical professionals with innovative products addressing unmet needs. Its vision is to advance a pipeline of truly innovative medicines through clinical development, aspiring to make a significant difference in patients’ lives by targeting conditions with high unmet medical needs.
VYNE Therapeutics has raised $51.0M across 1 funding round.
VYNE Therapeutics has raised $51.0M in total across 1 funding round.
# VYNE Therapeutics: Correcting the Record
VYNE Therapeutics is not a technology company—it is a biopharmaceutical company focused on developing therapies for immuno-inflammatory conditions.[1][3]
VYNE Therapeutics is a biopharmaceutical company committed to addressing unmet needs in patients with immuno-inflammatory conditions.[3] Rather than building software or hardware products, VYNE develops proprietary, innovative medicines designed to treat difficult therapeutic challenges.[1] The company operates as an entrepreneurial biotech firm that questions traditional assumptions in drug development and seeks to reimagine solutions for conditions with high unmet medical needs.[1]
The company is publicly traded on NASDAQ under the ticker VYNE, with a stock price of $0.58 as of December 31, 2025.[3]
VYNE's approach centers on several key principles:
The search results provided do not include details about VYNE's founding history, specific product pipeline, recent clinical trial results, or detailed financial performance—information that would be essential for a comprehensive company analysis. To provide a complete overview of VYNE's origin story, market position, and future outlook, additional sources would be needed.
VYNE Therapeutics has raised $51.0M in total across 1 funding round.
VYNE Therapeutics's investors include venBio, Aisling Capital, Bay City Capital, F-Prime Capital, Novo Holdings, Presidio Partners, Remeditex Ventures, Rock Springs Capital, Vivo Capital.
VYNE Therapeutics has raised $51.0M across 1 funding round. Most recently, it raised $51.0M Series C in July 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2017 | $51M Series C | — | VenBio Partners, Aisling Capital, BAY City Capital, F Prime Capital, Novo Holdings, Presidio Partners, Remeditex Ventures, Rock Springs Capital, Vivo Capital | Announced |